Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus type 2 antigen (inactivated) is a purified, formaldehyde-inactivated preparation of poliovirus type 2, typically derived from the MEF-1 strain. It is used as a component of inactivated poliovirus vaccines (IPV) for active immunization against poliomyelitis caused by poliovirus type 2. The antigen is produced by growing the virus in continuous lines of monkey kidney cells and then inactivating it with formaldehyde. Upon administration, it stimulates the immune system to produce neutralizing antibodies specific to poliovirus type 2 without causing disease, leading to reduced pharyngeal excretion and transmission potential upon exposure to live virus while providing individual protection from paralytic polio disease caused by serotype 2 infection.
Induces neutralizing antibody response via D-antigens
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Type 2 Antigen (Inactivated).